CompletedPhase 2NCT02336165

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Studying Germ cell tumor

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Ludwig Institute for Cancer Research
Principal Investigator: David A. Reardon, MD
Dana-Farber Cancer Institute
Intervention: Durvalumab(drug)
Enrollment: 159 target
Eligibility: 18 years · All sexes
Timeline: 2015 – 2021

Study locations (7)

Research Facility, Los Angeles, California, United States
Research Facility, San Francisco, California, United States
Research Facility, Baltimore, Maryland, United States
Research Facility, Boston, Massachusetts, United States
Research Facility, St Louis, Missouri, United States
Research Facility, New York, New York, United States
Research Facility, Melbourne, Australia

Collaborators

MedImmune LLC · Cancer Research Institute, New York City · Cure Brain Cancer Foundation, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02336165 on ClinicalTrials.gov

Other trials for Germ cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Germ cell tumor →

← Back to all trials